CA
NZ
UK
AU
IND
US
Edwards Lifesciences (NYSE:EW)has announced its founding sponsorship of the American Heart Association’s Heart Valve Initiative, a nationwide effort to enhance care and outcomes for approximately 28 million people worldwide living with heart valve disease. In the U.S., valve disease contributes to over 60,000 deaths …
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) released its financial results for the third quarter ended September 30, 2025, along with updates on recent strategic developments. The company, which focuses on oral delivery of biologics through its RaniPill® technology, highlighted new collaborations and capital inflows aimed …
Dexcom, Inc. (NASDAQ:DXCM)a global company specializing in continuous glucose monitoring technology, announced that the Québec government has extended public health coverage for its CGM systems under the Régie de l’assurance maladie du Québec. The update now includes eligible adults aged 18 and older with …
ImmunityBio, Inc. (NASDAQ:IBRX), a biotechnology firm advancing immunotherapies and cell-based treatments for cancer and infectious diseases, announced its financial and operational results for the third quarter and nine months ended September 30, 2025.
Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company developing RNA-based therapeutics, announced plans to present preclinical findings on its investigational obesity candidate WVE-007 (INHBE GalNAc-siRNA) at ObesityWeek® 2025, hosted byThe Obesity Societyin Atlanta.
DocGo Inc. (NASDAQ:DCGO), a provider of mobile health and technology-enabled medical transportation services, announced plans to roll out Longitudinal Care Services in collaboration with a California-based health insurance provider. The initiative aims to improve healthcare access for roughly 10,000 plan members who are currently …
Oxford Lane Capital Corp.(NASDAQ:OXLC)released its financial results for the second fiscal quarter ended September 30, 2025, alongside the declaration of monthly distributions on common stock for the first quarter of calendar year 2026.
Milestone Pharmaceuticals Inc.NASDAQ:MISTannounced that it will present new clinical data from its investigationaletripamil nasal spray program for paroxysmal supraventricular tachycardia at the American Heart Association Scientific Sessions 2025 in New Orleans, Louisiana.
Vir Biotechnology, Inc.NASDAQ:VIRhas completed participant enrollment in ECLIPSE 1, a Phase 3 clinical study evaluating the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) currently holds an average rating of“Reduce”as reported by MarketBeat Ratings. The review is based on evaluations from eight research firms.
Please wait processing your request...